体外检测阴道毛滴虫药物敏感性：与治疗成功相关的塞克硝唑最小致死浓度评估。
In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentration for Secnidazole That Correlates With Treatment Success.
机构信息
From the Division of Infectious Diseases, Department of Medicine.
Department of Microbiology.
出版信息
Sex Transm Dis. 2024 Nov 1;51(11):e43-e45. doi: 10.1097/OLQ.0000000000001992. Epub 2024 Apr 30.
Abstract
We determined the in vitro minimum lethal concentration of secnidazole and assessed the correlation with clinical susceptibility among Trichomonas vaginalis isolates obtained from 71 women, of whom 66 were successfully treated with this medication. A minimum lethal concentration ≤12.5 μg/mL correlated with clinical susceptibility in this study.
摘要
我们测定了 secnidazole 的体外最小致死浓度，并评估了其与 71 名女性阴道毛滴虫分离株临床药敏性之间的相关性，其中 66 名患者成功接受了该药物治疗。在本研究中，最小致死浓度≤12.5μg/ml 与临床药敏性相关。
相似文献
1
In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentration for Secnidazole That Correlates With Treatment Success.体外检测阴道毛滴虫药物敏感性：与治疗成功相关的塞克硝唑最小致死浓度评估。
Sex Transm Dis. 2024 Nov 1;51(11):e43-e45. doi: 10.1097/OLQ.0000000000001992. Epub 2024 Apr 30.
2
Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.阴道毛滴虫临床分离株对甲硝唑和塞克硝唑敏感性的研究。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02329-17. Print 2018 Apr.
3
[Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis].[阴道毛滴虫临床分离株体外甲硝唑耐药性的研究]
Mikrobiyol Bul. 2016 Oct;50(4):552-558. doi: 10.5578/mb.30140.
4
The genetic diversity of metronidazole susceptibility in Trichomonas vaginalis clinical isolates in an Egyptian population.埃及人群阴道毛滴虫临床分离株中甲硝唑敏感性的遗传多样性
Parasitol Res. 2017 Nov;116(11):3125-3130. doi: 10.1007/s00436-017-5627-3. Epub 2017 Sep 27.
5
Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.抗菌药物敏感性试验在临床治疗失败的阴道毛滴虫感染女性中的应用。
Sex Transm Dis. 2011 Oct;38(10):983-7. doi: 10.1097/OLQ.0b013e318224db39.
6
Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.阴道毛滴虫在青少年人群中的流行率、发生率、危险因素和抗生素耐药性。
Sex Transm Dis. 2010 Jul;37(7):440-4. doi: 10.1097/OLQ.0b013e3181cfcd8c.
7
Comparison of in vitro activity of metronidazole and garlic-based product (Tomex®) on Trichomonas vaginalis.甲硝唑和大蒜制品（Tomex®）体外抗阴道毛滴虫活性比较。
Parasitol Res. 2013 May;112(5):2063-7. doi: 10.1007/s00436-013-3367-6. Epub 2013 Mar 2.
8
Biological variability of Trichomonas vaginalis clinical isolates from symptomatic and asymptomatic patients.有症状和无症状患者阴道毛滴虫临床分离株的生物学变异性。
J Egypt Soc Parasitol. 2004 Dec;34(3):979-88.
9
The effect of iron on metronidazole activity against Trichomonas vaginalis in vitro.铁对甲硝唑体外抗阴道毛滴虫活性的影响。
Exp Parasitol. 2017 Nov;182:34-36. doi: 10.1016/j.exppara.2017.09.021. Epub 2017 Sep 19.
10
In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis.阴道毛滴虫对甲硝唑的体外敏感性及阴道滴虫病的治疗结果
Sex Transm Dis. 1988 Jan-Mar;15(1):17-24. doi: 10.1097/00007435-198801000-00004.
本文引用的文献
1
Where Do Tinidazole and Secnidazole Fit in With the Treatment of Trichomoniasis?替硝唑和塞克硝唑在滴虫病治疗中处于什么地位？
Sex Transm Dis. 2023 Oct 1;50(10):e17-e21. doi: 10.1097/OLQ.0000000000001850. Epub 2023 Jul 11.
2
Trichomoniasis.滴虫病。
Infect Dis Clin North Am. 2023 Jun;37(2):245-265. doi: 10.1016/j.idc.2023.02.001. Epub 2023 Mar 31.
3
The correlation between Trichomonas vaginalis infection and reproductive system cancer: a systematic review and meta-analysis.阴道毛滴虫感染与生殖系统癌症之间的相关性：一项系统评价和荟萃分析。
Infect Agent Cancer. 2023 Mar 2;18(1):15. doi: 10.1186/s13027-023-00490-2.
4
In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure.体外检测阴道毛滴虫药物敏感性：对应治疗失败的甲硝唑和替硝唑最小致死浓度评估。
Sex Transm Dis. 2023 Jun 1;50(6):370-373. doi: 10.1097/OLQ.0000000000001788. Epub 2023 Mar 24.
5
Secnidazole for Trichomoniasis in Women and Men.硝呋太尔用于治疗女性和男性滴虫病。
Sex Med Rev. 2022 Apr;10(2):255-262. doi: 10.1016/j.sxmr.2021.12.004. Epub 2022 Feb 10.
6
Sexually Transmitted Infections Treatment Guidelines, 2021.《2021年性传播感染治疗指南》
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1.
7
Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men.男性阴道毛滴虫病的流行病学、自然史、诊断和治疗。
Clin Infect Dis. 2021 Sep 15;73(6):1119-1124. doi: 10.1093/cid/ciab514.
8
Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis.滴虫病与不良出生结局：系统评价和荟萃分析。
BJOG. 2021 Nov;128(12):1907-1915. doi: 10.1111/1471-0528.16774. Epub 2021 Jun 27.
9
Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.单剂量口服塞克硝唑治疗女性滴虫病的疗效和安全性：3 期、随机、双盲、安慰剂对照、延迟治疗研究结果。
Clin Infect Dis. 2021 Sep 15;73(6):e1282-e1289. doi: 10.1093/cid/ciab242.
10
Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States.美国男女性人群中阴道毛滴虫感染的流行率及相关因素。
Clin Infect Dis. 2018 Jul 2;67(2):211-217. doi: 10.1093/cid/ciy079.
Zotero 插件